FDA Inspection
AstraZeneca Pharmaceuticals LPAstraZeneca Pharmaceuticals LP – FDA Inspection, Aug 17, 2018
Record Details
This FDA Inspection record concerns AstraZeneca Pharmaceuticals LP, with an inspection on August 17, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · e8cc1fea-3abb-4c6e-ba1a-26aa0b81097f
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1062666
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of AstraZeneca Pharmaceuticals LP
8| Date | Classification | Office | Project area |
|---|---|---|---|
| June 7, 2024 | Not classified | Baltimore District Office | |
| January 19, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 26, 2019 | Not classified | Baltimore District Office | |
| May 23, 2017 | Not classified | Baltimore District Office | |
| January 27, 2017 | Not classified | Baltimore District Office |
Other documents for AstraZeneca Pharmaceuticals LP
- FDA Inspection 1242118 - 2024-06-07
- FDA Inspection 1197584 - 2023-01-19
- FDA Inspection 1103507 - 2019-08-26
- FDA Inspection 1025484 - 2017-05-23
- FDA Inspection 1001245 - 2017-01-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.